文献速递生殖医学妇科

乳腺癌化疗后卵巢储备变化:生育力保存策略与年龄的影响

Ovarian reserve after chemotherapy in premenopausal women with breast cancer undergoing fertility preservation counselling with and without unilateral ovarian tissue cryopreservation.
PubMed 文献 · Hum Reprod · 2026-10-09

这项回顾前瞻性队列研究纳入152例接受生育力保存咨询的绝经前乳腺癌患者,评估化疗后卵巢储备(AMH和AFC)变化。化疗后AMH和AFC显著下降,2年内部分恢复;接受卵巢组织冷冻(OTC)和高龄(≥35岁)者下降更明显、恢复更有限。

要点

  • 化疗后AMH和AFC显著下降,2年内部分恢复。
  • 接受OTC和年龄≥35岁者卵巢储备下降更明显且恢复更有限。
  • 无OTC者AMH中位调整下降6个月90%、24个月75%。

核心结论

  • 化疗降低乳腺癌患者卵巢储备,接受OTC和高龄者下降更显著。

研究设计与样本

  • 回顾前瞻性队列研究,纳入152例18-42岁绝经前乳腺癌患者,2018年1月1日至2023年8月31日在哥本哈根大学医院接受生育力保存咨询。

主要发现

  • 化疗后AMH和AFC显著下降,2年内部分恢复。
  • 无OTC者AMH中位调整下降6个月90%[95%CI:85%,93%],24个月75%[95%CI:63%,83%]。
  • OTC者AMH中位调整下降6个月93%[95%CI:85%,95%],24个月85%[95%CI:78%,90%]。
  • AFC变化模式类似但幅度较小。

临床怎么用

  • 为乳腺癌患者提供化疗相关卵巢损伤的咨询,支持生育力保存决策。

局限性

  • 部分患者未完成全部随访评估。
  • 卵巢储备下降可能部分反映自然年龄相关 decline。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the impact of chemotherapy on the ovarian reserve in premenopausal women diagnosed with breast cancer, and how is this impacted by fertility preservation (FP) strategy and age at diagnosis? SUMMARY ANSWER: Chemotherapy reduces ovarian reserve in women with breast cancer, with the greatest reductions observed among women who underwent ovarian tissue cryopreservation (OTC) and those of advanced reproductive age (≥35 years). WHAT IS KNOWN ALREADY: Breast cancer is the most prevalent cancer among women of reproductive age, and in recent decades increasing emphasis has been placed on FP, including ovarian tissue, embryo, and oocyte cryopreservation. However, few large prospective studies have evaluated the effect of chemotherapy on ovarian reserve in patients with breast cancer using both anti-Müllerian hormone (AMH) and antral follicle count (AFC), and no large studies have assessed the impact by choice of FP. STUDY DESIGN, SIZE, DURATION: In this combined retro and prospective cohort study, we included 152 premenopausal women diagnosed with breast cancer who received FP counselling at Rigshospitalet, Copenhagen University Hospital, between 1 January 2018 and 31 August 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 18-42 years scheduled for FP counselling before chemotherapy were included. Exclusion criteria were previous chemotherapy, oophorectomy, and death or emigration within 2 years of inclusion. Medical and gynecological history, and oncological treatment plans were recorded. Ovarian reserve was assessed using AMH and AFC at baseline and at 6, 12, and 24 months after chemotherapy. Changes over time were analyzed using linear mixed models adjusted for age at baseline and hormonal contraceptive use. MAIN RESULTS AND THE ROLE OF CHANCE: Of 152 women, 57 underwent OTC, while 41 underwent oocyte/embryo cryopreservation and 54 had no FP. Baseline median AMH was 13.9 [95% CI: 10.7, 18.1] pmol/l among women who did not undergo OTC and 13.3 [10.9, 16.3] pmol/l among those who did. A marked reduction in both AMH and AFC was observed after chemotherapy, with partial recovery within 2 years after treatment. The reduction was more pronounced, and recovery more limited, in women with OTC and in those of advanced reproductive age (≥35 years). Compared to baseline, the adjusted reduction in median AMH was 90% [95% CI: 85%, 93%] at 6 months and 75% [95% CI: 63%, 83%] at 24 months in women without OTC and 93% [95% CI: 85%, 95%] and 85% [95% CI: 78%, 90%] in women with OTC, respectively. Similar patterns, however, not as profound, were seen for AFC. LIMITATIONS, REASONS FOR CAUTION: Not all women completed assessments at all three follow-up visits, likely reflecting emotional exhaustion, hospital fatigue, reluctance to attend additional appointments, or changes in reproductive intentions. Furthermore, the observed reduction in ovarian reserve may, to some extent, also reflect the natural age-related decline in ovarian reserve. WIDER IMPLICATIONS OF THE FINDINGS: These findings may support counselling women with breast cancer about chemotherapy-related ovarian damage and thus the need for FP. FUNDING: The study is funded by the Independent Research Fund Denmark (Grant ID 10.46540/4308-00130B). DISCLOSURES: A.P. has received grants (paid to the institution) and consulting fees from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Cryos; honoraria from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Organon; and support for meeting attendance and/or travel (paid to the institution) from Gedeon Richter. A.T.P. received speaker fees from Astellas, Gedeon-Richter, and Novo Nordisk. These companies had no role in the study. The other authors have no conflicts or interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Yde AM, Colmorn LB, Pinborg A, et al. Ovarian reserve after chemotherapy in premenopausal women with breast cancer undergoing fertility preservation counselling with and without unilateral ovarian tissue cryopreservation. Hum Reprod. 2026. PMID: 42853979. doi:10.1093/humrep/deag156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。